Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation - The Journal of Headache and Pain
Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01456-2
Background Calcitonin gene-related peptide (CGRP) inhibitors have been developed as options for treatment of chronic and episodic migraine. We present our experience of the use of erenumab in a tertiary...
Conclusion: Erenumab was an effective treatment for chronic migraine in this treatment resistant population over 3 months of follow up. Presence of daily headache predicted poorer response but there was still a significant positive response rate in this group.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrIt is good to see if these medications still help in the difficult to treat patient.
Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients - Neurological Sciences
Source : https://link.springer.com/article/10.1007/s10072-022-06265-8
Background Migraine is a disabling primary headache disorder with socioeconomic burden. Medication overuse headache (MOH) is caused by chronic overuse of symptomatic drugs often observed in migraine patients. The approved...
Conclusion: Monoclonal antibodies inhibiting CGRP are effective in reducing monthly headache days in migraine patients with MOH.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrThis is a great review since MOH is so applicable in many patients.
Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials - The Journal of Headache and Pain
Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01470-4
Background Erenumab, a fully human monoclonal antibody that targets the calcitonin gene-related peptide receptor, has demonstrated efficacy and safety in the prevention of episodic and chronic migraine. There exists an...
Conclusions: Erenumab (70 mg or 140 mg) exhibited a similar safety profile compared with placebo across age groups in individuals with episodic or chronic migraine, with no increased emergence of events due to age. Erenumab was well tolerated in older participants with multiple comorbidities, polypharmacy, and age-related physiological changes.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrThis is a great review on the safety.
Efficacy and Safety of Erenumab, Galcanezumab, and Fremanezumab in the Treatment of Drug-Resistant Chronic Migraine: Experience in Real Clinical Practice - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35979920/
doi: 10.1177/10600280221118402. Online ahead of print. 1 Servicio de Farmacia, Complejo Hospitalario Universitario de Canarias, Tenerife, Spain. 2 Servicio de Neurología, Complejo Hospitalario Universitario de Canarias, Tenerife, Spain. doi: 10.1177/10600280221118402....
Conclusions: The results confirm the effectiveness and safety of anticalcitonin gene-related peptide (CGRP) drugs in real clinical practice. However, the study shows little benefit from erenumab intensification, with similar effectiveness and worse tolerability than the standard dose.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrGreat to see real life data.
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain Versus Moderate or Severe Pain - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35977836/
Relative to attacks treated with moderate or severe pain, treatment with ubrogepant during mild pain resulted in significantly higher rates of freedom from pain, freedom from associated symptoms, and achieving...
Conclusion: Relative to attacks treated with moderate or severe pain, treatment with ubrogepant during mild pain resulted in significantly higher rates of freedom from pain, freedom from associated symptoms, and achieving normal function two hours after administration.(Funded by Allergan plc [prior to acquisition by AbbVie]; ClinicalTrials.gov.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrThis can be helpful in setting up when to take which medication.
-
Dr Hamid3yrInteresting review to examine the efficacy of ubrogepant in the treatment of migraine with mild versus moderate or severe pain.